Analysis of the Potential Angiogenic Mechanisms of BuShenHuoXue Decoction against Osteonecrosis of the Femoral Head Based on Network Pharmacology and Experimental Validation

Abstract

Objective: Osteonecrosis of the femoral head (ONFH) is a common orthopedic disease with a high disability rate. The clinical effect of BuShenHuoXue decoction (BSHX) for ONFH is satisfactory. We aimed to elucidate the potential angiogenic mechanisms of BSHX in a rat femoral osteonecrosis model and bone marrow mesenchymal stem cells (BMSCs).

Methods: With in vivo experiments, we established the steroid-induced osteonecrosis of the femoral head (SONFH) model using Sprague–Dawley (SD) rats (8-week-old). The rats were randomly divided into five group of 12 rats each and given the corresponding interventions: control, model (gavaged with 0.9% saline), BSHX low-, medium- and high-dose groups (0.132 3, 0.264 6, and 0.529 2 g/mL BSHX solution by gavage). After 12 weeks, haematoxylin and eosin (H&E) staining was preformed to evaluate rat osteonecrosis. the expression of angiogenic factors (CD31, VEGFA, KDR, VWF) in rat femoral head was detected by immunohistochemistry, qPCR and western blotting. In cell experiment, BMSCs were isolated and cultured in the femoral bone marrow cavity of 4-week-old SD rats. BMSCs were randomly divided into eight groups and intervened with different doses of BSHX-containing serum and glucocorticoids: control group (CG); BSHX low-, medium-, and high-dose groups (CG + 0.661 5, 1.323, and 2.646 g/kg BSHX gavage rat serum); dexamethasone (Dex) group; and Dex + BSHX low-, medium-, and high-dose groups (Dex + 0.661 5, 1.323, and 2.646 g/kg BSHX gavaged rat serum), the effects of BSHX-containing serum on the angiogenic capacity of BMSCs were examined by qPCR and Western blotting. A co-culture system of rat aortic endothelial cells (RAOECs) and BMSCs was then established. Migration and angiogenesis of RAOECs were observed using angiogenesis and transwell assay. Identification of potential targets of BSHX against ONFH was obtained using network pharmacology.

Results: BSHX upregulated the expression of CD31, VEGFA, KDR, and VWF in rat femoral head samples and BMSCs (p < 0.05, vs. control group or model group). Different concentrations of BSHX-containing serum significantly ameliorated the inhibition of CD31, VEGFA, KDR and VWF expression by high concentrations of Dex. BSHX-containing serum-induced BMSCs promoted the migration and angiogenesis of RAOECs, reversed to some extent the adverse effect of Dex on microangiogenesis in RAOECs, and increased the number of microangiogenic vessels. Furthermore, we identified VEGFA, COL1A1, COL3A1, and SPP1 as important targets of BSHX against ONFH.

Conclusion: BSHX upregulated the expression of angiogenic factors in the femoral head tissue of ONFH model rats and promoted the angiogenic capacity of rat RAOECs and BMSCs. This study provides an important basis for the use of BSHX for ONFH prevention and treatment.

Keywords

Bioinformatics / Molecular mechanisms of pharmacological action / Osteonecrosis of the femoral head (ONFH) / Traditional Chinese medicine (TCM)

References

[1] ZhaoDW, YuM, HuK, WangW, YangL, Wang BJ, et al. Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: results from a nationally representative survey. Chin Med J (Engl). 2015;128(21):2843–2850.

[2] TanB, LiW, ZengP, Guo H, HuangZ, FuF, et al. Epidemiological study based on China osteonecrosis of the femoral head database. Orthop Surg. 2021;13(1):153–160.

[3] LiuF, WangW, YangL, Wang B, WangJ, ChaiW, et al. An epidemiological study of etiology and clinical characteristics in patients with nontraumatic osteonecrosis of the femoral head. J Res Med Sci. 2017;22:15.

[4] MontMA, SalemHS, PiuzziNS, Goodman SB, JonesLC. Nontraumatic osteonecrosis of the femoral head: where do we stand today?: a 5-year update. J Bone Joint Surg Am. 2020;102(12):1084–1099.

[5] GuggenbuhlP, RobinF, CadiouS, Albert JD. Etiology of avascular osteonecrosis of the femoral head. Morphologie. 2021;105(349):80–84.

[6] FengY, YangSH, XiaoBJ, Xu WH, YeSN, XiaT, et al. Decreased in the number and function of circulation endothelial progenitor cells in patients with avascular necrosis of the femoral head. Bone. 2010;46(1):32–40.

[7] ChenCY, DuW, RaoSS, et al. Extracellular vesicles from human urine-derived stem cells inhibit glucocorticoid-induced osteonecrosis of the femoral head by transporting and releasing pro-angiogenic DMBT1 and anti-apoptotic TIMP1. Acta Biomater. 2020a;111:208–220.

[8] XuH, WangC, LiuC, PengZ, LiJ, JinY, et al. Cotransplantation of mesenchymal stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis of the femoral head. Stem Cells Transl Med. 2021;10(5):781–796.

[9] CuiQ, JoWL, KooKH, Cheng EY, DrescherW, GoodmanSB, et al. ARCO consensus on the pathogenesis of non-traumatic osteonecrosis of the femoral head. J Korean Med Sci. 2021;36(10):e65.

[10] GuoXF, XuR, RenYL. Discussion on the scientific connotation of traditional Chinese medicine in preventing and treating steroid-induced necrosis of the femoral head based on the theory of “osteogenic angiogenic coupling”. Chin Arch Tradit Chin Med. 2023;1–9.

[11] XuHH, LiSM, FanMQ, Fang L, NiMT, TongPJ. Effects of PRP combined with Taohong Siwu decoction on the expression of VEGF, CD31, ALP and β-catenin in the femoral head tissues of rats with steroid-induced avascular necrosis of femoral head. China J Tradit Chin Med Pharm. 2020;35(3):1501–1504.

[12] ZhangY, LiG. A meta-analysis of efficacy of the invigorating the kidney and promoting blood circulation therapy on femoral head necrosis. Clin J Chin Med. 2021;13(14):139–145.

[13] ChungBH, KimJD, KimCK, Kim JH, WonMH, LeeHS, et al. Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun. 2008;376(2):404–408.

[14] HeY, KamH, WuX, ChenQ, LeeSMY. Dual effect of aucubin on promoting VEGFR2 mediated angiogenesis and reducing RANKL-induced bone resorption. Chin Med. 2023;18(1):108.

[15] ChengXH, YangXX, CuiHR, Zhang BB, ChenKD, YangXY, et al. Chuanxiong improves angiogenesis via the PI3K/AKT/Ras/MAPK pathway based on network pharmacology and DESI-MSI metabolomics. Front Pharmacol. 2023;14:1135264.

[16] ClarkJD, Gebhart GF, GonderJC, KeelingME, KohnDF. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38(1):41–48.

[17] KilkennyC, BrowneWJ, CuthillIC, Emerson M, AltmanDG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.

[18] CookHV, Doncheva NT, SzklarczykD, von MeringC, JensenLJ. Viruses. STRING: a virus-host protein-protein interaction database. Viruses. 2018;10(10):519.

[19] RuJ, LiP, WangJ, Zhou W, LiB, HuangC, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Chem. 2014;6:13.

[20] ZhangQ, JinLV, JinL. Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J Int Med Res. 2018;46(6):2141–2148.

[21] HolmesK, Roberts OL, ThomasAM, CrossMJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003–2012.

[22] HongJM, KimTH, KimHJ, Park EK, YangEK, KimSY. Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med. 2010;42(5):376–385.

[23] PrivratskyJR, NewmanPJ. PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res. 2014;355(3):607–619.

[24] QuanR, DuW, ZhengX, et al. VEGF165 induces differentiation of hair follicle stem cells into endothelial cells and plays a role in in vivo angiogenesis. J Cell Mol Med. 2017;21(8):1593–1604.

[25] HouJ, WangL, WuQ, ZhengG, LongH, Wu H, et al. Long noncoding RNA H19 upregulates vascular endothelial growth factor a to enhance mesenchymal stem cells survival and angiogenic capacity by inhibiting miR-199a-5p. Stem Cell Res Ther. 2018;9(1):109.

[26] HuK, OlsenBR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone. 2016;91:30–38.

[27] HuK, OlsenBR. Vascular endothelial growth factor control mechanisms in skeletal growth and repair. Dev Dyn. 2017;246(4):227–234.

[28] ZhaoH, Yeersheng R, XiaY, KangP, WangW. Hypoxia enhanced bone regeneration through the HIF-1α/β-catenin pathway in femoral head osteonecrosis. Am J Med Sci. 2021;362(1):78–91.

[29] HolmqvistK, CrossMJ, RolnyC, Hägerkvist R, RahimiN, MatsumotoT, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267–22275.

[30] ChenK, LiuY, HeJ, PavlosN, WangC, Kenny J, et al. Steroid-induced osteonecrosis of the femoral head reveals enhanced reactive oxygen species and hyperactive osteoclasts. Int J Biol Sci. 2020b;16(11):1888–1900.

[31] YuH, LiuP, ZuoW, SunX, LiuH, LuF, et al. Decreased angiogenic and increased apoptotic activities of bone microvascular endothelial cells in patients with glucocorticoid-induced osteonecrosis of the femoral head. BMC Musculoskelet Disord. 2020;21(1):277.

[32] SunF, ZhouJL, WeiSX, Jiang ZW, PengH. Glucocorticoids induce osteonecrosis of the femoral head in rats via PI3K/AKT/FOXO1 signaling pathway. PeerJ. 2022;10:e13319.

[33] GuoJ, GaoY, ZhaoBN. Progress of research methods of traditional Chinese medicine compound serum pharmacology. Chin J Tradit Chin Med Pharm. 2017;32(4):1656–1658.

[34] WongSK, ChinKY, Ima-nirwanaS. Quercetin as an agent for protecting the bone: a review of the current evidence. Int J Mol Sci. 2020;21(17):6448.

[35] ZhouYN, WuYQ, JiangXQ, Zhang X, XiaL, LinK, et al. The effect of quercetin on the Osteogenesic differentiation and angiogenic factor expression of bone marrow-derived mesenchymal stem cells. PLoS ONE. 2015;10(6):e0129605.

[36] ZhangY, SongL, CaiL, WeiR, HuH, JinW. Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food Chem Toxicol. 2013;53:325–333.

[37] KimMH, RyuSY, BaeMA, Choi JS, MinYK, KimSH. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem Toxicol. 2008;46(11):3375–3382.

[38] WangF, WangN, GaoY, ZhouZ, LiuW, PanC, et al. β-Carotene suppresses osteoclastogenesis and bone resorption by suppressing NF-κB signaling pathway. Life Sci. 2017;174:15–20.

[39] OkuraT, SekiT, SuzukiK, Ishiguro N, HasegawaY. Serum levels of carotenoids in patients with osteonecrosis of the femoral head are lower than in healthy, community-living people. J Orthop Surg (Hong Kong). 2018;26(2):2309499018770927.

[40] ChoiEM. Modulatory effects of luteolin on osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. Cell Biol Int. 2007;31(9):870–877.

[41] TangSY, HuMH, ZhouRY, et al. Study on the effects and mechanism of luteolin on osteogenic repair of bone defects. Chin Pharm. 2023;34(7):807–813.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.